AI-Guided Hematoma Aspiration vs. Conservative Treatment for Spontaneous ICH
Key facts
- Who runs it
- Xiaolei Chen
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 680 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 30 Jun 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- AI-Assisted Navigated Hematoma Aspiration
- Conservative Treatment
- Record updated
- 27 April 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Confirmed supratentorial hypertensive intracerebral hemorrhage on brain CT scan
- Hematoma volume 20-50mL
- Patients with with GCS score ≥8
- Admitted within 24h of ictus
Who cannot take part
- Concurrent head injury or history of head injury
- Severe concomitant diseases that affect life expectancy
- Intracerebral hemorrhage caused by tumor, coagulopathy, aneurysm, or arteriovenous malformation
- Multiple intracerebral hemorrhage
- With severe intraventricular hemorrhage
- Known advanced demential or disability before
- Pregnant women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The effectiveness of traditional craniotomy in the treatment of intracerebral hemorrhage remains controversial. Minimally invasive surgery, specially, image-guided hematoma aspiration, proves to be effective and may have some advantages compared with craniotomy. This multicenter randomized controlled trial aims to evaluate and compare the clinical efficacy of two minimally invasive treatment strategies for patients with spontaneous supratentorial intracerebral hemorrhage (ICH) with moderate hematoma volume (20-50 mL): (1) AI-assisted, navigation-guided hematoma aspiration, and (2) targeted pharmacological therapy. This study is designed to address the current lack of prospective comparative evidence between advanced image-guided surgical intervention and medical management in this specific patient population. By focusing on functional recovery, hematoma resolution, and safety outcomes, this trial seeks to provide high-quality evidence to guide treatment decision-making and optimize individualized care for patients with spontaneous ICH.
The 2 groups in the trial
- AI-Assisted Navigated Hematoma AspirationTreatment being tested
This technique integrates AI-driven imaging analysis with navigation systems to enable accurate targeting and aspiration of intracerebral hematomas through a burr-hole approach, reducing surgical trauma and improving functional outcomes.
- Conservative TreatmentExisting treatment, for comparison
Conservative treatment for intracerebral hemorrhage involves medical management without surgical intervention, focusing on stabilizing the patient, controlling blood pressure, managing intracranial pressure, and preventing secondary complications.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of AI-assisted Navigated Hematoma Aspiration With Conservative Treatment for Spontaneous Intracerebral Hemorrhage: A Multicenter Randomized Controlled Trial
- Fit questions
- Built from NCT07077343, who can take part
- Publications
- Record updated
- 27 April 2026